Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
Key takeaways
- Rep. Taylor’s modest Amgen purchase is a routine disclosure that may hint at his view of the biotech firm but is unlikely to sway the stock on its own.
- Transaction date: September 22, 2026
- Purchase value range: $1,001–$15,000
- Amgen share price: $404.19 (down 0.76%)
What happened
Ohio Representative David Taylor filed a purchase of Amgen (NASDAQ: AMGN) on September 22, 2026, with the transaction value reported between $1,001 and $15,000. The filing lists the purchase as part of a broader set of trades totaling more than $357,000 over the past three years, including sales of Microsoft and purchases of Home Depot and Marathon Petroleum. Amgen shares were trading at $404.19, down 0.76% at the time of the report.
Why it matters
Congressional stock trades are required to be disclosed under the STOCK Act, and investors often watch them for potential insider sentiment. A purchase by a member of Congress can signal confidence in a company’s prospects, while a sale may indicate a lack of confidence or a need to diversify holdings. Taylor’s trade…
Short-term and longer-term
Short-term. In the next few days, traders may look for any short‑term price reaction to the disclosure, especially if the trade coincides with other market-moving news.
Longer-term. Over the coming months, investors might consider Taylor’s trade as one data point in assessing Amgen’s long‑term prospects.